GSK used a ploy known as “device hopping,” in which a branded inhaler is retired and succeeded by a follow-on inhaler with the same active ingredients but new patent and regulatory protection periods.

New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm The FDA-approved strength for both COPD and asthma is fluticasone furoate / ...

Submission supported by pivotal CAPTAIN study demonstrating statistically significant improvement in lung function compared with the ICS/LABA, Relvar/Breo Ellipta At least 30% of asthma patients ...

Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) can cause side effects that range from mild to serious. More common side effects include headache and ...

Vectura Group announces global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio Upfront payment of US$15m Up to US$80m of development milestone payments Mid teen percentage ...

Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is a brand-name inhaler prescribed for COPD and asthma. Trelegy Ellipta has interactions with some other drugs ...

Partnership reinforces Propeller Health's leadership in respiratory digital health and creates a joint opportunity to advance treatment of respiratory disease through digital innovation MADISON, ...